The write-up you posted on AMRN and Pronova appears to be comparing apples and oranges. Pronova’s revenues are in the form of royalties from GSK and other licensees, but the author uses the worldwide in-market sales of Lovaza (under various aliases) as a datapoint in the valuation analysis.
Market Data 
Markets 
AI
